5-(3-amino-benzyl)-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine | 1080827-86-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: 5-(3-amino-benzyl)-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine
• 英文别名: 5-[(3-Aminophenyl)methyl]-7-cyclopentylpyrrolo[2,3-d]pyrimidin-4-amine
• CAS: 1080827-86-6
• 化学式: C₁₈H₂₁N₅
• 分子量: 307.398
• InChiKey: NBYULDMYLCHGCZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  82.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-(3-amino-benzyl)-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine 、 2,6-二氟苯磺酰氯 生成 N-[3-(4-amino-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-5-ylmethyl)-phenyl]-2,6-difluoro-benzenesulfonamide
  参考文献：
  名称：

  Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors

  摘要：

  The synthesis and biological evaluation of novel Tie-2 kinase inhibitors are presented. Based on the pyrrolopyrimidine chemotype, several new series are described, including the benzimidazole series by linking a benzimidazole to the C5-position of the 4-amino-pyrrolopyrimidine core and the ketophenyl series synthesized by incorporating a ketophenyl group to the C5-position. Medicinal chemistry efforts led to potent Tie-2 inhibitors. Compound 15, a ketophenyl pyrrolopyrimidine urea analog with improved physicochemical properties, demonstrated favorable in vitro attributes as well as dose responsive and robust oral tumor growth inhibition in animal models. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.03.012

文献信息

• [EN] PYRROLOPYRIMIDINE DERIVATIVES<br/>[FR] DERIVES DE PYRROLOPYRIMIDINE
  申请人：PFIZER PROD INC

  公开号：WO2004056830A1

  公开（公告）日：2004-07-08

  The invention relates to compounds of the formula 1or a pharmaceutically acceptable salt, prodrug or hydrates thereof, wherein Q, A, L, R1, R2 and R3 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula 1.

  这项发明涉及公式1的化合物或其药学上可接受的盐、前药或水合物，其中Q、A、L、R1、R2和R3如本文所定义。该发明还涉及含有公式1化合物的药物组合物，以及通过给予公式1化合物来治疗哺乳动物的过度增殖性疾病的方法。
• Pyrrolopyrimidine derivatives
  申请人：La Greca D. Susan

  公开号：US20050037999A1

  公开（公告）日：2005-02-17

  The invention relates to compounds of the formula 1 or a pharmaceutically acceptable salt, prodrug or hydrates thereof, wherein Q, A, L, R 1 , R 2 and R 3 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula 1.

  本发明涉及式1的化合物或其药学上可接受的盐、前药或水合物，其中Q、A、L、R1、R2和R3的定义如本文所述。本发明还涉及含有式1化合物的药物组合物，以及通过给予式1化合物治疗哺乳动物的增殖过度疾病的方法。
• PYRROLOPYRIMIDINE DERIVATIVES
  申请人：Pfizer Products Inc.

  公开号：EP1578751A1

  公开（公告）日：2005-09-28
• US7271262B2
  申请人：——

  公开号：US7271262B2

  公开（公告）日：2007-09-18
• Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors
  作者：Joel T. Arcari、Jean S. Beebe、Martin A. Berliner、Vincent Bernardo、Merin Boehm、Gary V. Borzillo、Tracey Clark、Bruce D. Cohen、Richard D. Connell、Heather N. Frost、Deborah A. Gordon、William M. Hungerford、Shefali M. Kakar、Aaron Kanter、Nandell F. Keene、Elizabeth A. Knauth、Susan D. LaGreca、Yong Lu、Louis Martinez-Alsina、Matthew A. Marx、Joel Morris、Nandini C. Patel、Doug Savage、Cathy I. Soderstrom、Carl Thompson、George Tkalcevic、Norma J. Tom、Felix F. Vajdos、James J. Valentine、Patrick W. Vincent、Matthew D. Wessel、Jinshan M. Chen

  DOI：10.1016/j.bmcl.2013.03.012

  日期：2013.5

  The synthesis and biological evaluation of novel Tie-2 kinase inhibitors are presented. Based on the pyrrolopyrimidine chemotype, several new series are described, including the benzimidazole series by linking a benzimidazole to the C5-position of the 4-amino-pyrrolopyrimidine core and the ketophenyl series synthesized by incorporating a ketophenyl group to the C5-position. Medicinal chemistry efforts led to potent Tie-2 inhibitors. Compound 15, a ketophenyl pyrrolopyrimidine urea analog with improved physicochemical properties, demonstrated favorable in vitro attributes as well as dose responsive and robust oral tumor growth inhibition in animal models. (C) 2013 Elsevier Ltd. All rights reserved.